Sanpower seals groundbreaking medical deal

Conglomerate boosts China's push to revolutionise its health sector by buying US biotech pioneer Dendreon. It complements Sanpower's previous investment in more prosaic health assets.

A vacuum in quality healthcare has emerged as a key challenge for the world's most populous nation, as policymakers wrestle with problems including a shortage of skilled professionals, slow drug clearance procedures and services that are unaffordable to most ordinary Chinese.

President Xi Jinping put the issue in perspective at August's National Healthcare Conference when he said it was at the heart of the country's policy-making machinery. State leaders later approved the “Healthy China 2030” blueprint, the first long-term national strategic plan for the sector since 1949.

Acquisitive Chinese firms, always sensitive to the mood of the national leadership, have been quick to add health...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222